Trudy Knight is based in the Institute of Occupational and Environmental Medicine at the University of Birmingham. She has experience of working in various aspects of toxicology, pharmacology and pharmacy in environments of academia, pharmaceutical industries, and the National Health Service.
Ph.D in Molecular Toxicology, Imperial College of Science, Technology and Medicine, at St. Mary’s Hospital Medical School, London
D.I.C in Molecular Toxicology, , Imperial College of Science, Technology and Medicine, at St. Mary’s Hospital Medical School, London
MRSC. (Member of the Royal Society of Chemistry)
Member of the British Pharmacological Society
M.Sc in Toxicology, University of Birmingham
Member of the Royal Pharmaceutical Society of Great Britain
B.Sc (Hons) in Pharmaceutical Sciences, Aston University
Registered Pharmaceutical Chemist with General Pharmaceutical Council
Registered Toxicologist with The Society of Biology, British Toxicology Society and EuroTox
Trudy Knight embarked on a career in pharmaceutical sciences, with the aim of gaining substantial experience in all aspects of Professional Pharmacy. She worked in several NHS Hospitals, in various specialities, including Clinical Ward Pharmacy, Pharmaceutical Manufacture of sterile and non-sterile products, Quality Control (Analytical Chemistry and Microbiology), Drug Information and Teaching pre-registration Pharmacists.
Throughout this time, she developed, not only her original interest in pharmacology and therapeutics, but also in the adverse effects of drugs, safe prescribing, and skills in production of personalised formulations to avoid toxicity, in particular for dermatological conditions and paediatric patients. She is particularly interested in manifestation and mechanisms of idiosyncratic drug reactions. Her PhD study was on the molecular basis of immune-mediated hepatotoxicity induced by halothane, in the Department of Pharmacology and Toxicology, at St. Mary’s Hospital Medical School, London.
Trudy further expanded her experience in pharmaceutical toxicological work by employments in Academia, and in Pharmaceutical Industries (Roche Pharmaceuticals plc, and Faulding Pharmaceuticals plc.) in areas of Pharmacologjcal and Toxicological Research, Regulatory Affairs, Evidence Based Pharmacotherapy, Systematic Reviews and Health Technology Assessments, and Teaching Pharmacology. At the University of Birmingham, she has worked on the Birmingham Graduate Entry (MBChB) Course (GEC).
Trudy also has concern for human safety following inhalational exposures to chemicals in the environment and occupations, and is presently based in the Institute of Occupational and Environmental Medicine at the University of Birmingham. She is currently working (p/t) as Project Manager of the large multidisciplinary academic nano- research project, FABLE (From Airborne Exposures to Biological Effects: the impact of nanoparticles on human health) funded (£2.2million) by NERC/MRC. The research investigates the nature of metal nanoparticles found in ambient and indoor environments, synthesis and characterisation of metal nanoparticles, investigation of their ability to cross cellular membranes and their intracellular behaviour, and their toxicity in various cell types in vitro, and in in vivo models. The work is done in several laboratories across Birmingham University campus, at the University of Aberdeen and at Public Health England in Oxford. Trudy is also involved with environmental and health government organisations, with the aim of finally transferring outcomes of the project to inform policy.
Trudy lectures on the MSc in Occupational Health (Institute of Occupational and Environmental Medicine), and is Personal Tutor for this course, and also for the MSc in Toxicology (School of Biosciences).
Supervision of projects of 2-3 students per year for the MSc in Occupational Health
Idiosyncratic drug reactions, in particular immune-mediated reactions to drugs.
Mechanisms of adverse reactions to drugs
Safe prescribing (especially in paediatrics and the elderly)
Nano materials (Toxicity and pharmaceutical use)
Legal regulation of occupational and environmental exposures to nanomaterials.
IARC Monograph 108 Some Drugs and Herbal Medicines
2013, Trudy was invited by The International Agency for Research on Cancer (IARC) (part of the World Health Organisation (WHO), to join the Working Group of 23 international scientists to evaluate the carcinogenicity of 14 drugs and herbal products, at an 8-day meeting in Lyon, France in June.
The meeting summary has been published in Lancet Oncology (August 2013), and the complete IARC Monograph Volume 108 ‘Some Drugs and Herbal Medicines’, written by all members of the Working Group, will be published by IARC later in 2013.
Trudy also undergoes various consultancies for Legal and Government agencies.
Memberships of Scientific Societies & Positions held
Member of UK Clinical Pharmacy Association
The Biochemical Society
UK Environmental Mutagen Society (UKEMS) (Molecular Epidemiology Group)
The British Toxicology Society (BTS)
Positions held with the The British Toxicology Society:
o Member of the Communications Sub-Committee – 2007-2013
o Secretary of the Communications Sub-Committee – 2008-2013
o Member of the BTS Editorial Board - 2007 ongoing